Tuberculosis (TB) is a chronic infectious disease caused by (), mainly transmitted through droplets to infect the lungs, and seriously affecting patients' health and quality of life. Clinically, anti-TB drugs often entail side effects and lack efficacy against resistant strains. Thus, the exploration and development of novel targeted anti-TB medications are imperative. Currently, protein-protein interactions (PPIs) offer novel avenues for anti-TB drug development, and the study of targeted modulators of PPIs in has become a prominent research focus. Furthermore, a comprehensive PPI network has been constructed using computational methods and bioinformatics tools. This network allows for a more in-depth analysis of the structural biology of PPIs and furnishes essential insights for the development of targeted small-molecule modulators. Furthermore, this article provides a detailed overview of the research progress and regulatory mechanisms of PPI modulators in , the causative agent of TB. Additionally, it summarizes potential targets for anti-TB drugs and discusses the prospects of existing PPI modulators.

中文翻译：

---

针对结核分枝杆菌中蛋白质-蛋白质相互作用的调节剂

结核病（TB）是由（）引起的慢性传染病，主要通过飞沫传播感染肺部，严重影响患者的健康和生活质量。临床上，抗结核药物通常会产生副作用，并且对耐药菌株缺乏疗效。因此，探索和开发新型靶向抗结核药物势在必行。目前，蛋白质-蛋白质相互作用（PPI）为抗结核药物的开发提供了新的途径，PPI靶向调节剂的研究已成为一个突出的研究热点。此外，利用计算方法和生物信息学工具构建了一个全面的 PPI 网络。该网络可以更深入地分析 PPI 的结构生物学，并为开发靶向小分子调节剂提供重要见解。此外，本文还详细概述了结核病病原体中 PPI 调节剂的研究进展和调控机制。此外，它还总结了抗结核药物的潜在靶点，并讨论了现有 PPI 调节剂的前景。